MedTrace Logo

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

NCT03187691 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-03-08

No results posted yet for this study

Summary

A Non-randomized, prospective , multicenter, open uncontrolled study in patients with acute myelogenous (AML) or lymphoblastic leukaemia (ALL)

Conditions

Interventions

DRUG

Oral Encochleated Amphotericin B (CAMB)

Lipid-crystal nano-particle formulation amphotericin B

Sponsors & Collaborators

  • University of Cologne

    collaborator OTHER

  • The Clinical Trials Centre Cologne

    collaborator OTHER

  • Matinas BioPharma Nanotechnologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Oliver Cornely, MD · University of Cologne

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03187691 on ClinicalTrials.gov